Mereo BioPharma Group plc (MREO) stock
MREONasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.28−0.01 (-4.94%)
Close on Nov 19, 2026Market cap $43.92MP/E –Yield –
Mereo BioPharma operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Mereo BioPharma's operating income for the twelve months ending Sep 30, 2026 was -$30.40M. For fiscal 2025 it was -$40.11M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$40.11M | – |
| FY2024 | Dec 31, 2024 | -$47.36M | – |
| FY2023 | Dec 31, 2023 | -$28.42M | – |
| FY2022 | Dec 31, 2022 | -$54.43M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$6.22M | – |
| Q2 FY2026 | Jun 30, 2026 | -$7.03M | – |
| Q1 FY2026 | Mar 31, 2026 | -$8.77M | – |
| Q4 FY2025 | Dec 31, 2025 | -$8.39M | – |
| Q3 FY2025 | Sep 30, 2025 | -$10.02M | – |
| Q2 FY2025 | Jun 30, 2025 | -$10.50M | – |
| Q1 FY2025 | Mar 31, 2025 | -$11.20M | – |
| Q4 FY2024 | Dec 31, 2024 | -$15.28M | – |
| Q3 FY2024 | Sep 30, 2024 | -$9.37M | – |
| Q2 FY2024 | Jun 30, 2024 | -$12.81M | – |
| Q1 FY2024 | Mar 31, 2024 | -$9.90M | – |
| Q4 FY2023 | Dec 31, 2023 | -$7.13M | – |
| Q3 FY2023 | Sep 30, 2023 | -$9.07M | – |
| Q2 FY2023 | Jun 30, 2023 | -$811.00K | – |
| Q1 FY2023 | Mar 31, 2023 | -$11.41M | – |
See a number that looks wrong?